What Dog Longevity Study Dropout Rates Mean
A calm veterinary explainer on dropout rates in dog longevity studies, attrition bias, and how to read results.
A dropout rate means how many dogs left early, and why those missing dogs change what results mean.
On this page
A longevity headline often reports who finished. The dropout rate reports who did not, and that missing group shapes how much weight the finished results can carry.
The fork: missing dogs or missing answers
A dropout rate is the proportion of enrolled dogs that do not complete the planned follow-up or outcome assessment. A dog can move away, develop an unrelated illness, die, stop tolerating the product, or the owner can withdraw consent or stop returning questionnaires.
That is common variation in long studies. Senior dogs develop new conditions, owners change schedules, and travel for rechecks gets harder over months. The threshold that warrants an examination is different: a cluster of withdrawals for vomiting, diarrhea, itching, lethargy, or loss of appetite in one group.
Marcia, who lives in Elgin, Illinois with Ludo, an 8-year-old neutered male Miniature Dachshund, shows the decision point. She read a one-year aging study where 22 of 140 dogs did not finish, then asked whether the product had failed those dogs or life had intervened. The paper’s flow diagram, not the marketing summary, held the answer.
Good reports publish that diagram. The BMJ CONSORT explanation asks trial authors to show how many participants were randomized, received treatment, completed follow-up, and were analyzed, with reasons for loss at each stage. Without those counts, a reader cannot tell random loss from selective loss.

Why dogs leave early, and why the reason matters
Random loss weakens precision. Selective loss can shift direction.
If dogs leave for reasons tied to treatment or outcome — poor palatability, digestive upset, worsening mobility, or owners who perceive no benefit — the dogs that remain are no longer a balanced comparison. This is attrition bias: the analyzed groups differ from the randomized groups in ways that can make a product look better or worse than it is.
Intention-to-treat analysis is one protection. It keeps every randomized dog in the assigned group for analysis, even when dosing stopped early.
Regulators describe the same principle in statistical guidance. The U.S. Food and Drug Administration E9 guidance on statistical principles for clinical trials discusses intention-to-treat, full analysis sets, and how protocol deviations and withdrawals affect interpretation.
Missing data still require assumptions. No method recovers unmeasured outcomes with certainty.
The National Academies Press report on missing data in clinical trials recommends preventing missing data first, documenting reasons for every withdrawal, and testing whether conclusions hold under different assumptions about the missing values. Sensitivity analysis is the plain-language test: does the benefit survive if the missing dogs fared worse than assumed?
How to read the number in practice
Start with three checks before looking at the benefit claim.
First, compare rates by group. A 6% withdrawal rate in control and a 24% rate in treatment deserves more scrutiny than 15% in both groups, even when the total is identical.
Second, read reasons, not just totals. Moves, schedule conflicts, and unrelated injuries point toward noise. Adverse events, palatability refusal, owner-perceived lack of effect, and loss to follow-up after worsening signs point toward possible selection.
Third, look for the analysis population. Results limited to completers answer a narrower question: what happened among dogs able and willing to stay on protocol. Results that include all randomized dogs, with a stated method for missing outcomes, answer the broader clinical question.
A short rule helps.
High, uneven, or poorly explained loss lowers confidence, even when the graph looks favorable.
That distinction changes what an owner does next. For context on why canine data deserve separate scrutiny from laboratory or human work, see Dog Studies vs. Human Studies for Supplements: What Actually Transfers. For how early-life enrollment lengthens the window for loss, see Should You Start Longevity Supplements Before Your Dog Shows Signs of Aging?. For separating a plausible aging mechanism from proof of longer life, see Anti-Aging Pills for Dogs: What the Evidence Actually Supports.
When dropout points back to your own dog
A study dropout table does not diagnose Ludo or any other dog. It tells an owner which questions merit a visit.
Bring the label, the dose given, start date, missed doses, appetite, stool, water intake, activity, and any new medication. Ask whether the sign fits expected variation with age, a dietary or activity change, or a threshold that warrants an examination with bloodwork, orthopedic assessment, or another targeted test.
I hold one position on longevity claims until stronger evidence arrives: a low, balanced, well-explained dropout rate keeps a study readable, while a high or one-sided rate keeps the claim provisional. What would change my view is a pre-registered canine trial with complete follow-up, published reasons for every withdrawal, intention-to-treat results, and sensitivity analyses that hold steady. Most supplement summaries do not yet meet that bar.
If a product page cites longevity results without enrollment counts, completion counts, or withdrawal reasons, treat the result as incomplete rather than persuasive.
Frequently asked questions
What is a normal dropout rate in a dog study?
There is no single normal number. Short palatability trials may lose few dogs, while year-long senior-dog studies often lose more to moves, illness, death, and missed visits. Compare rates between groups and read the stated reasons.
Does a high dropout rate mean the supplement is unsafe?
Not by itself. It means confidence drops until the reasons are clear. Withdrawals for digestive signs, itching, lethargy, or poor appetite in one group deserve veterinary discussion, while moves and scheduling conflicts usually reflect study logistics.
What should I look for instead of the headline result?
Enrollment number, number completing each group, reasons for each withdrawal, whether analysis included all randomized dogs, and whether the finding held under different assumptions about missing dogs.
Sources
- CONSORT 2010 statement: explanation and elaboration — BMJ
- E9 Statistical Principles for Clinical Trials — U.S. Food and Drug Administration
- The Prevention and Treatment of Missing Data in Clinical Trials — National Academies Press